Table 1

 Characteristics of the subjects studied

SubjectNOD2 statusSexAt time of venesectionDisease classification*
Age (y)IBD drugsActivityAge at diagnosis (y)LocationBehaviour
*According to the Vienna classification.33
NOD2, nucleotide binding oligomerisation domain 2; IBD, inflammatory bowel disease; GI, gastrointestinal.
HC1wt/wtM31.8
HC2wt/wtF49.1
HC3wt/wtF38.4
HC4wt/wtF37.3
HC5wt/wtM46.0
HC6wt/wtM30.3
HC7wt/wtM27.9
CD11007fs/1007fsF36.1NilQuiescent<40IleocolonPenetrating
CD21007fs/1007fsF77.8NilQuiescent⩾40IlealStricturing
CD31007fs/1007fsM51.3NilQuiescent<40IlealStricturing
CD41007fs/1007fsM27.05-ASA, prednisoloneActive<40IlealStricturing
CD5908Arg/1007fsM23.0NilQuiescent<40IlealPenetrating
CD6908Arg/1007fsF36.65-ASAQuiescent<40IlealPenetrating
CD7908Arg/1007fsF59.3NilQuiescent<40IlealStricturing
CD8908Arg/1007fsM55.9NilQuiescent<40IleocolonPenetrating
CD9702Trp/1007fsF30.9NilQuiescent<40Upper GIStricturing
CD10702Trp/1007fsF56.3PrednisoloneQuiescent<40IleocolonStricturing
CD11702Trp/1007fsF42.4NilQuiescent<40IlealStricturing
CD12702Trp/1007fsM19.2AzathioprineQuiescent<40IleocolonStricturing
CD13702Trp/1007fsF32.6AzathioprineQuiescent<40IlealStricturing
CD14702Trp/1007fsM41.1NilQuiescent<40IlealStricturing
CD15702Trp/702TrpM46.9NilQuiescent<40IlealPenetrating
CD16702Trp/702TrpF63.2NilQuiescent⩾40IlealStricturing
CD17702Trp/702TrpF48.1NilQuiescent⩾40IlealStricturing
CD18702Trp/702TrpM28.2AzathioprineActive<40Upper GIPenetrating
CD19702Trp/702TrpF31.35-ASAQuiescent<40IlealStricturing